Abstract 3129
Background
The tumor suppressor TP53 is the most frequently mutated gene in solid tumors. Although TP53 decides cell fate and governs initiation of apoptosis, inhibitors targeting mutant TP53 did not yet reached clinical use. Our goal was to identify new potential therapeutic targets in TP53 mutant solid tumors by in silico analysis of multiple large, independent next-generation sequencing and gene chip datasets.
Methods
First, gene expression and mutation data from multiple solid tumors were collected from TCGA and METABRIC databases. Samples were separated based on TP53 mutation status, mutational type and tumor type to identify targetable genes. Differential gene expression was compared using Mann-Whitney test between the mutated (disruptive mutations only) and wild type patient cohorts across all genes. Then, the prognostic value of identified genes was validated in a gene chip-based dataset obtained from the GEO repository. Survival analysis was performed using Cox proportional hazards regression. Significance threshold was set at p < 0.01. Finally, False Discovery Rate was computed to correct for multiple hypothesis testing.
Results
The TCGA dataset include 9,720 patients (21 different cancer types), the Metabric dataset (breast cancer) 1,399 patients, and the GEO dataset (breast, lung, and brain tumors) 7,386 patients. Only genes with higher expression in the TP53 mutant cohort were selected and the list of the top targets was further filtered to include only druggable kinases. The best performing kinases include MPS1 (p = 2.9E-58, FC = 2.82), PLK1 (p = 2.6E-55, FC = 2.55), MELK (p = 5.2E-54, FC = 2.81), and AURKB (p = 2E-53, FC = 3.23). Each of these kinases had a significant prognostic power as well. Of the top 2 (MPS1 and PLK1), both have multiple inhibitors available (for other indications) with PLK1 closest to the clinical use.
Conclusions
Our results suggest that MPS1 (monopolar spindle 1 kinase) and PLK1 (polo like kinase 1) kinases are the strongest druggable targets in TP53 mutant solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Semmelweis University.
Funding
National Research, Development and Innovation Office, Hungary.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract